U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19ClN2
Molecular Weight 310.8212
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESLORATADINE

SMILES

c1cc2CCc3cc(ccc3C(=C4CCNCC4)c2nc1)Cl

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI

Molecular Formula C19H19ClN2
Molecular Weight 310.8212
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1008892800000
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1008892800000
Palliative
CLARINEX

Approved Use

Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.

Launch Date

1008892800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4 ng/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
Disc. AE: Somnolence, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Somnolence (1 patient)
Abdominal pain (1 patient)
Sources:
45 mg 1 times / day multiple, oral
Highest studied dose
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M+F
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
Somnolence 1 patient
Disc. AE
1.25 mg 1 times / day steady, oral
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 2-11 years
Health Status: unhealthy
Age Group: 2-11 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
not significant [IC50 43 uM]
strong [Ki 1.3 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
weak [Inhibition 10 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
likely
no (pharmacogenomic study)
Comment: pharmacogenotype 2C19 does not correlate with systemic exposure
Page: 19
likely
no (pharmacogenomic study)
Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation
Page: 10
likely
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Page: 10
yes
yes
weak (co-administration study)
Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively.
Tox targets
PubMed

PubMed

TitleDatePubMed
Second-generation antihistamines in asthma therapy: is there a protective effect?
2002
Advances in allergy management.
2002
Impact and modulation of nasal obstruction.
2002
Chronic urticaria: impact of allergic inflammation.
2002
Therapeutic points of intervention and clinical implications: role of desloratadine.
2002
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays.
2002
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.
2002
Lack of clinically relevant interaction between desloratadine and erythromycin.
2002
Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.
2002
A pharmacokinetic profile of desloratadine in healthy adults, including elderly.
2002
Oral bioavailability of desloratadine is unaffected by food.
2002
Desloratadine demonstrates dose proportionality in healthy adults after single doses.
2002
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
2002
Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor.
2002 Aug 9
The new antihistamines--desloratadine and levocetirizine: a review.
2002 Dec
[The place of new antihistamines in allergy management. Apropos of desloratadine].
2002 Dec
Comparative pharmacology of H1 antihistamines: clinical relevance.
2002 Dec 16
Treatment of allergic rhinitis.
2002 Dec 16
[The result of neglected or erroneous treatment. Mentally handicapped by hay fever].
2002 Jul 11
Gateways to clinical trials.
2002 May
Clinical pharmacology of H1-antihistamines in the skin.
2002 Nov
Desloratidine for the treatment of chronic urticaria.
2002 Oct
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.
2002 Oct
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.
2002 Oct
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion.
2002 Sep-Oct
Chronic urticaria: a role for newer immunomodulatory drugs?
2003
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
2003 Apr
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
2003 Aug
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.
2003 Aug
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.
2003 Aug 13
Gateways to clinical trials.
2003 Dec
Interactions of olopatadine and selected antihistamines with model and natural membranes.
2003 Dec
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
2003 Feb
Desloratadine: a nonsedating antihistamine.
2003 Feb
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.
2003 Jan 6
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
2003 Jul
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma.
2003 Jul
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.
2003 Jun
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.
2003 Jun
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.
2003 Jun
Gateways to clinical trials. March 2003.
2003 Mar
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum.
2003 Mar
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.
2003 Mar
P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
2003 Mar
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].
2003 May 25
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.
2003 Oct
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.
2003 Oct
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.
2003 Oct
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.
2003 Oct 25
Gateways to clinical trials.
2004 Jan-Feb
Patents

Sample Use Guides

Adults and Adolescents 12 Years of Age and Over:
Route of Administration: Oral
In Vitro Use Guide
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:08:37 UTC 2021
Edited
by admin
on Fri Jun 25 21:08:37 UTC 2021
Record UNII
FVF865388R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DESLORATADINE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LORATADINE RELATED COMPOUND A [USP]
Common Name English
8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-BPYRIDINE
Common Name English
DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE RATIOPHARM
Brand Name English
8-CHLORO-6,11-DIHYDRO-11(4-PIPERIDYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-B) PYRIDINE
Common Name English
DENOSIN
Brand Name English
DESLORATADINE [INN]
Common Name English
DASSELTA
Brand Name English
NSC-759824
Code English
DESLORATADINE [MART.]
Common Name English
RUPATADINE FUMARATE IMPURITY B [EP]
Common Name English
NEOCLARITYN
Brand Name English
DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [MI]
Common Name English
DESLORATADINE [VANDF]
Common Name English
DESLORATADINE [USP-RS]
Common Name English
LORATADINE SPECIFIED IMPURITY D [EP]
Common Name English
DESLORATADINE [USP MONOGRAPH]
Common Name English
CLARINEX
Brand Name English
DESCARBOETHOXYLORATADINE
Common Name English
DESLORATADINE ACTAVIS
Brand Name English
DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)
Brand Name English
DESLORATADINE [ORANGE BOOK]
Common Name English
8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDINYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE
Common Name English
CLARINEX-D COMPONENT DESLORATADINE
Common Name English
DESLORATADINE [WHO-DD]
Common Name English
OPULIS
Brand Name English
SCH-34117
Code English
AZOMYR
Brand Name English
ALLEX
Brand Name English
DESLORATADINE TEVA
Brand Name English
AERIUS
Brand Name English
DESLORATADINE [JAN]
Common Name English
LORATADINE RELATED COMPOUND A [USP-RS]
Common Name English
DESLORATADINE [EMA EPAR]
Common Name English
DESLORATADINE [EP MONOGRAPH]
Common Name English
DESLORATADINE [USAN]
Common Name English
DESLORATADINE COMPONENT OF CLARINEX-D
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
LIVERTOX 284
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
WHO-VATC QR06AX27
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS OPULIS (WITHDRAWN: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NCI_THESAURUS C29578
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NDF-RT N0000175587
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
WHO-ATC R06AX27
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AERINAZE (AUTHORIZED: RHINITIS)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
EMA ASSESSMENT REPORTS NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
NDF-RT N0000000190
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
Code System Code Type Description
USP_CATALOG
1370280
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY USP-RS
USP_CATALOG
1173042
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL1172
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
DRUG BANK
DB00967
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
MESH
C121345
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
INN
7817
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
RXCUI
275635
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY RxNorm
EPA CompTox
100643-71-8
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
LACTMED
Desloratadine
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
NCI_THESAURUS
C47474
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
PUBCHEM
124087
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
DRUG CENTRAL
814
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
FDA UNII
FVF865388R
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
WIKIPEDIA
Desloratadine
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
IUPHAR
7157
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
MERCK INDEX
M4193
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY Merck Index
EVMPD
SUB01596MIG
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
CAS
100643-71-8
Created by admin on Fri Jun 25 21:08:37 UTC 2021 , Edited by admin on Fri Jun 25 21:08:37 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Ki
METABOLIC ENZYME -> NON-INHIBITOR
METABOLIC ENZYME -> NON-INHIBITOR
BINDER->LIGAND
BINDING
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> NON-INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
WEAK
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
WEAK
TARGET -> INHIBITOR
Kd
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
WEAK
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> NON-INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
PARENT -> METABOLITE ACTIVE
MAJOR
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE

ONCE DAILY

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC